Batavia, UvA sign STEP technology licensing deal

As per the deal, Batavia gains exclusive license to the technology developed at CellaGenics, an UvA Holding company.

Batavia CEO Menzo Havenga said, "We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP™ technology since we firmly believe that this technology will significantly reduce manufacturing costs."

STEP technology considerably reduces the time required to develop recombinant protein-producing mammalian cell lines at the same time boosting protein production by ten times, claimed the company.

UvA director Piet Scholten said, "With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!"

Financial details of the deal have not been disclosed.